Drug-coated balloons (DCB)

Giannopoulos Drug-Eluting Stent Figure 1

Original Contribution

Concomitant Drug-Coated Balloon Angioplasty With Bail-Out Use of Eluvia Drug-Eluting Stent: Is There Any Downside to a Double Dose of Paclitaxel?

06/01/2022

Eric A. Secemsky , MD, MSc, RPVI, FACC, FAHA, FSCAI;

Ehrin J. Armstrong , MD, MSc, FACC;

Stefanos Giannopoulos , MD;

The application of 2 distinct and simultaneously applied drug-delivery platforms for the treatment of peripheral artery disease has not been studied. This study investigated the outcomes of femoropopliteal disease treated with drug-coated...

The application of 2 distinct...

06/01/2022

Journal of Invasive Cardiology

Paclitaxel DCB 12-Month PREVAIL Study Results Figure 1

Original Contribution

Paclitaxel Drug-Coated Balloon for the Treatment of De Novo Small-Vessel and Restenotic Coronary Artery Lesions: 12-Month Results of the Prospective, Multicenter, Single-Arm PREVAIL Study

11/01/2021

Cheryl Shen , MS;

Gwenn Wetzels , PhD;

Luca Testa , MD, PhD;

Joseph "Jo" Dens , MD, PhD;

Mark S. Patterson , MBBS, PhD, MD, MRCP;

Azeem Latib , MD, BCh, MBBCh;

Patrizio Lancellotti , MD, PhD;

Pierfrancesco Agostoni , MD, PhD;

Frankie C.C. Tam , MD;

Carl Schotborgh , MD;

Elvin Kedhi , MD;

Pieter R. Stella , MD, PhD;

The PREVAIL study evaluated the safety and effectiveness of a paclitaxel DCB for the treatment of coronary de novo and ISR lesions in patients with symptomatic ischemic heart disease.

The PREVAIL study evaluated the...

11/01/2021

Journal of Invasive Cardiology

Case Report

Long-Term Patency of a Drug-Coated Balloon in the Treatment of Upper Extremity Peripheral Artery Disease

05/10/2020

Syed M. Ahmed , MD;

Angiography showed a severe proximal subclavian artery stenosis adjacent to the origin of the left vertebral artery. There was concern that a stent might jail the left vertebral artery.

Angiography showed a severe...

05/10/2020

Cath Lab Digest

Calcium Corner

Lower Paclitaxel Dose, Smaller Delivery Platform: 12-Month Data From the RANGER SFA II Trial

01/01/2020

Ravish Sachar , MD, FACC;

Dr. Sachar presented 12-month data from the RANGER II SFA trial of the Ranger drug-coated balloon (DCB) (Boston Scientific) on November 5th at the 2019 Vascular InterVentional Advances (VIVA) conference in Las Vegas, Nevada.

Dr. Sachar presented 12-month...

01/01/2020

Cath Lab Digest

FDA Panel

The Future is Going to Be Drug-Coated or Drug-Eluting. We Need Individual Patient Data to Move Forward

07/31/2019

Konstantinos Katsanos , MSc, MD, PhD;

There seems to be some sort of heterogeneity between the mortality risk and the baseline patient characteristics. We need to be able to explore this more thoroughly before we make any decisions about how to continue using paclitaxel. We need...

There seems to be some sort of...

07/31/2019

Cath Lab Digest

FDA Panel

Perspectives on the Use of Paclitaxel-Eluting Balloons in the Lower Extremities

07/31/2019

Daniel G. Clair , MD;

Since a large portion of my practice consists of patients with complex lesions, I have continued to use these devices extensively and will plan to continue using them as I currently do.

Since a large portion of my...

07/31/2019

Cath Lab Digest